Mode
Text Size
Log in / Sign up
Phase 4 N=65 Randomized Triple-blind Treatment

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Bipolar Depression

Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Response to Treatment — 21; 9; 6; 11 Participants — p=.02

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Escitalopram (Drug); Celecoxib (Drug); Placebo (Drug)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Loyola University
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Response to Treatment
21; 9; 6; 11 .02 sig
PRIMARY
Disease Remission
17; 2; 10; 18 <.001 sig

Summary

This project will attempt to enhance and augment the antidepressant efficacy of a commonly used antidepressant in poorly responding bipolar depressed patients.

Eligibility Criteria

Inclusion Criteria

  • Ages 21 - 65 years old at time of screening visit. Both genders and any race will be accepted.
  • Diagnosis of BPD I or II without significant co-morbid secondary medical or psychiatric diagnoses; no substance abuse or dependence during preceding 12 months
  • A minimum score of 18 on the first 17 items of the 21-item Hamilton Depression Scale
  • Willingness to washout for a reasonable time (depending on the substance) from: Vitamin E and fish oils (>600 IU/day), non-aspirin NSAIDs or aspirin (>81 mg/day, H2 receptor antagonists, Ginko biloba, caffeine on morning of blood drawing, and to institute lights-out at 23:00 hours on the nights before blood drawings

Exclusion Criteria

  • Any abnormal findings on the physical exam, ECG, blood/urine or minor infections
  • Any pre-existing physical pain condition, including fibromyalgia
  • History of peptic ulcer complicated by perforation, hemorrhage, or obstruction; symptoms of peptic ulcer within 4 weeks of enrollment date
  • Any substance abuse or dependence during the preceding 12 months
  • Clinically significant hypertension, anemia, liver disease, kidney disease, arthritis, diabetes, recurrent migraines, epilepsy, stroke, gum disease, autoimmune disease
  • Current use of lithium
  • Current use of a stimulant
  • Certain steroids including use of hormonal birth control and any systemic or topical corticosteroids (hormone replacement therapy will be allowed)
  • Unwillingness to refrain from H2 receptor antagonists, non-aspirin NSAIDs, or aspirin (more than 1 mg/day).
  • Use of any anticoagulant agents
  • Use of nicotine-containing substances. Subjects who quit smoking more than 3 months prior to assessment may be considered for the study
  • Known sensitivity or allergy to the study medications or a need to receive agents that are contra-indicated in combination with CBX or ESC
  • Unwillingness to fast and abstain from caffeine on mornings of blood drawings
  • A sleep disorder other than insomnia or hypersomnia as a distinct symptom of major depressive disorder (MDD)
  • Inability to commit to the follow-up visits between 8 and 11 am
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01479829). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search